Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Sales of Investments

Cash received from selling or redeeming investments.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $54.65M fell 64.5% year over year, behind the -52.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at -3.7% a year.

Context

  • Sales of investments amounted to 1040788.9% of revenue in FY2025, up 140885.6 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -64.5% toward the trailing-twelve-month pace of -52.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$54.65M+3.3% QoQ
Last fiscal yearDec 2025
$374.68M-31.7% YoY
LTMMar 2026
$275.21M-52.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.5%——
1 year-31.7%——
3-year CAGR-3.7%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
374.68M USD
Year-over-year change
-31.7%
4-year CAGR
-11.7%

Sales of Investments vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -52.0% is the 8th highest of 9, against a peer median of -13.2%.
  • Sales of investments amounts to 887777.4% of revenue for LYEL, versus a peer median of 449.1%.
LYEL Competitors
Sales of Investments for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$385.18M USD-2.0%+109.8%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$275.21M USD-52.0%-3.7%887777.4%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$249.82M USD-36.1%-13.3%—
AMRNAmarin Corporation plcLTM Mar 2026$196.48M USD-13.0%-6.6%91.4%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$146M USD-24.5%+62.7%—
SLNSilence Therapeutics plcLTM Mar 2026$101.74M USD——11040.3%
CABACabaletta Bio, Inc.LTM Mar 2026$100.96M USD+104.0%+26.0%—
EDITEditas Medicine, Inc.LTM Mar 2026$82.51M USD-64.2%-31.5%213.2%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$65M USD-13.3%+11.8%—
GNLXGenelux CorporationLTM Mar 2026$32.28M USD+25.4%—403500.0%
ACIUAC Immune S.A.LTM Dec 2025CHF 16.05M CHF——449.1%
Peer median (excluding LYEL) —-13.2%+11.8%449.1%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.